Jan 2, 2024, 09:24 by

Huateng Pharma introduces Tetrahydrocurcumin, a dual-action antioxidant and skin-whitening agent, alongside Pro-xylane and (S)-Pro-xylane, potent anti-ageing agents, and Piroctone Olamine, an effective anti-dandruff solution, emphasizing a commitment to quality and versatility from lab to commercial scale.

Jan 2, 2024, 09:24 by

Jan 2, 2024, 09:24 by

Jan 2, 2024, 09:23 by

Jan 2, 2024, 09:23 by

Jan 2, 2024, 09:23 by

Jan 2, 2024, 09:23 by

Jan 2, 2024, 09:23 by

Dec 28, 2023, 01:00 by User Not Found

Clinical Research News | Medidata has launched the Medidata Research Alliance; BC Platforms has acquired Medexprim, a leading European real-world data company; Velocity Clinical Research has expanded into Poland and acquired its first site, ClinMedica Research; and more.

Dec 27, 2023, 01:00 by User Not Found

Clinical Research News | The Patient-Centered Outcomes Research Institute (PCORI) approves funding awards to support 20 new patient-centered comparative clinical effectiveness research (CER) studies; Freya Biosciences intends to advance the clinical development of its lead drug candidate; Sanofi enters a multi-year research collaboration with French pharmatech company Aqemia; and more.

Dec 20, 2023, 09:15 by

Dec 20, 2023, 09:15 by

Abzena, a leading CDMO for biologics, collaborates with the FDA on a publication endorsing the MHC Associated Peptide Proteomics (MAPPs) assay for assessing immunogenicity in drug development. The article underscores MAPPs' precision in identifying potential immunogenicity risks in early preclinical stages, reducing the likelihood of anti-drug antibodies (ADAs) and optimizing biologics. Abzena integrates MAPPs into its immunogenicity services, aiming to de-risk drug development. The Chief Scientific Officer, Dr. Campbell Bunce, emphasizes the assay's value in informing drug regions that may induce ADAs. The collaboration aims to expedite safer, more effective therapies for patients

Dec 20, 2023, 01:00 by User Not Found

Clinical Research News | Medication adherence in phase 2 and phase 3 clinical trials is far less perfect than the 98% often cited in peer-reviewed published papers on those studies. While solutions to address it exist in the form of smart packaging, the will to adopt such technologies has been tepid, leading to widespread overdosing of trial participants—most notably those who take the drug as instructed—and, ultimately, directions for use on drug labels and unnecessary side effects once the drug hits the market.

Dec 19, 2023, 09:36 by

Hope you are well and are having a great week so far! I just wanted to pass on the latest news from Recipharm, who has chosen Veeva Systems to streamline global quality operations. The move aims to enhance oversight, resource efficiency, validation speed, and inspection readiness. The full release is below. Thank you Charlotte

Dec 19, 2023, 01:00 by User Not Found

Clinical Research News | The SCOPE team just announced the finalists in the inaugural Site Innovation Award, recognizing sites and partnerships pioneering new approaches to improve clinical trials. The winner will be announced at the Summit for Clinical Ops Executives in Orlando, February 11-14, 2024.

Dec 18, 2023, 08:48 by

Dec 18, 2023, 08:48 by

Oz-UK Ltd announces the installation of its new low-GWP (global warming potential) manufacturing line.

Dec 18, 2023, 08:48 by

Dec 18, 2023, 08:48 by

Leading computational biology company PrecisionLife®, which is driving precision medicine in complex chronic diseases, the ME/CFS charity Action for M.E., and the MRC Human Genetics Unit at the Institute of Genetics and Cancer, University of Edinburgh have been awarded a £622,000 grant by Innovate UK's Advancing Precision Medicine programme to improve diagnosis and treatment for the millions of people affected by ME/CFS and long Covid.

Dec 15, 2023, 09:47 by

I just wanted to follow up to see if you had received my initial email regarding ReciBioPharm partners with Acuitas Therapeutics? Please let me know if there is any further information you require from me for this.